2023-10-24 10:50
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2024
The 2023 Annual General Meeting resolved that the Chairman of the Board shall convene the three largest shareholders in the company in terms of voting...
Message from the CEO Our Phase-III study, the largest of its kind ever conducted, is progressing across 88 hospitals in ten countries. We have now recruited...
2023-07-31 10:00
New number of shares and votes in IBT
The number of shares and votes in Infant Bacterial Therapeutics AB (publ) has changed due to the recently completed rights issue (for further information...
2023-07-04 08:30
IBT announces outcome of its rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA...
2023-07-03 16:39
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks...
2023-06-21 17:20
The futility analysis for IBT’s Connection Study positive
“IBT announced earlier today that the Data Monitoring Committee (DMC) has performed the planned safety analysis of the study data of 1,403 babies...
2023-06-21 08:55
IBT continues to recruit prematurely born infants to The Connection Study following a planned safety analysis.
In accordance with the study protocol, the independent Data Monitoring Committee (DMC) has performed the final planned safety analysis of Infant Bacterial...
Infant Bacterial Therapeutics AB (IBT) announces today that the European Patent Office has approved its patent application for Lactobacillus reuteri. The...
2023-06-13 11:15
IBT publishes prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA...
2023-06-09 11:04
Extraordinary General Meeting of Infant Bacterial Therapeutics
At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it was resolved to approve the Board of Directors&rsquo...